Výsledky vyhledávání - "Roger Dansey"

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Autor: Ian W. Flinn, Ronald L. Dubowy, Steven Coutre, Yeonhee Kim, David W. Johnson, Siddhartha Mitra, Jan A. Burger, Andrew D. Zelenetz, Albert S. Yu, Michael J. Keating, Langdon L. Miller, Nicole Lamanna, Susan O'Brien, Leanne Holes, Thomas J. Kipps, Roger Dansey

Publikováno v: Blood. 126:2686-2694

Idelalisib is a first-in-class oral inhibitor of PI3Kδ that has shown substantial activity in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). To evaluate idelalisib as initial therapy, 64 treatment-naive older patients with CLL

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00e69695ec278100b3df187745f246e6
https://doi.org/10.1182/blood-2015-03-630947

Zobrazit plný text záznamu

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Autor: Roger von Moos, Geoffrey Smith, Amy Feng, Penella J. Woll, Howard S. Yeh, Luis Costa, David H. Henry, Saroj Vadhan-Raj, Roger Dansey, Susie Jun, Vania Hungria, Vera Hirsh, Giorgio V. Scagliotti

Publikováno v: Supportive Care in Cancer. 22:679-687

Bone complications of metastatic disease, including skeletal-related events (SREs), impair patients' functioning and quality of life. In a randomized, phase 3 trial of 1,776 patients with metastases from solid tumors (except breast or prostate) or mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::989fa1473958a929f042ae14e4be565c
https://doi.org/10.1007/s00520-013-2022-1

Zobrazit plný text záznamu

Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time

Autor: Neal D. Shore, Gavin Marx, Paul Sieber, Fred Saad, Carsten Goessl, Juan Morote, Stéphane Oudard, Ronaldo Damião, Peter J. Van Veldhuizen, Karim Fizazi, Zhishen Ye, Matthew R. Smith, Roger Dansey, Kurt Miller, Bertrand Tombal

Publikováno v: Journal of Clinical Oncology. 31:3800-3806

Purpose Denosumab, an anti–RANK ligand monoclonal antibody, significantly increases bone metastasis–free survival (BMFS; hazard ratio [HR], 0.85; P = .028) and delays time to first bone metastasis in men with nonmetastatic castration-resistant pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::386615c4b92a351a07d3257c33a6a5fa
https://doi.org/10.1200/jco.2012.44.6716

Zobrazit plný text záznamu

The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction

Autor: Roger Dansey, Leonid Katz, William C. Dougall, Paul J. Kostenuik, Holly Brenza Zoog, Rachel B. Wagman, Ada Braun, Carsten Goessl

Publikováno v: Annals of the New York Academy of Sciences. 1263:29-40

Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function, and survival of osteoclasts. The role of excessive RANKL as a contributor to conditions characterized by bone loss or bone

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::363105ccc4219786ba889ca610622e00
https://doi.org/10.1111/j.1749-6632.2012.06674.x

Zobrazit plný text záznamu

Plný text ve formátu HTML

Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer

Autor: Teuvo L.J. Tammela, Benjamin Z. Leder, Matthew R. Smith, Paul Sieber, Fred Saad, Carsten Goessl, Roger Dansey, R B Egerdie, Jiri Heracek, Chunlei Ke

Publikováno v: Prostate Cancer and Prostatic Diseases. 15:308-312

Denosumab, a fully human monoclonal antibody against RANK ligand, increased bone mineral density (BMD) and reduced fracture risk vs placebo in a phase 3 trial in men with prostate cancer on androgen deprivation therapy (ADT). The present analysis of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d337c654906ee9547d7274ee5f4d47d
https://doi.org/10.1038/pcan.2012.18

Zobrazit plný text záznamu

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

Autor: Roger Dansey, William J. Boyle, Paul J. Kostenuik, William C. Dougall, Javier San Martin, John K. Sullivan, W. Scott Simonet, David L. Lacey

Publikováno v: Nature Reviews Drug Discovery. 11:401-419

Bone is a complex tissue that provides mechanical support for muscles and joints, protection for vital organs, a mineral reservoir that is essential for calcium homeostasis, and the environment and niches required for haematopoiesis. The regulation o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e408fe34082f8a4a5a98f65e5099197
https://doi.org/10.1038/nrd3705

Zobrazit plný text záznamu

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Autor: Roger Dansey, Lawrence Karsh, Neal D. Shore, Piotr Milecki, Janet E. Brown, Ronaldo Damião, Michael Rader, H. Wang, Karim Fizazi, Qi Jiang, Sylvia Tadros, Matthew R. Smith, Carsten Goessl, Michael A. Carducci

Publikováno v: The Lancet. 377:813-822

Summary Background Bone metastases are a major burden in men with advanced prostate cancer. We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic acid for prevention of skeletal-related events in men with bone metastases f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfd80137bee3389538909e1166127a15
https://doi.org/10.1016/s0140-6736(10)62344-6

Zobrazit plný text záznamu

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

Autor: María Viniegra, Richard De Boer, Katia Tonkin, Denise A. Yardley, Jean-Jacques Body, Qi Jiang, Allan Lipton, Yasuhiro Fujiwara, Ada Braun, Michelle Fan, Roger Dansey, Guenther G. Steger, Susie Jun, Mikhail Lichinitser, Alison Stopeck

Publikováno v: Journal of Clinical Oncology. 28:5132-5139

Purpose This randomized study compared denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor κ B (RANK) ligand, with zoledronic acid in delaying or preventing skeletal-related events (SREs) in patients with breast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e607ab306202ef3a33b7c16b4ab92336
https://doi.org/10.1200/jco.2010.29.7101

Zobrazit plný text záznamu

Abstract P6-14-01: Effect of Denosumab Versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone Metastases: Results from the Extended Blinded Treatment Phase

Autor: Toshimi Takano, C. Van Poznak, Alison Stopeck, Ada Braun, Miguel Martín, Alexander H.G. Paterson, Diana Ritchie, M. Viniegra, H Bourgeois, Jacek Jassem, Michelle Fan, Roger Dansey, J.J. Body

Publikováno v: Cancer Research. 70:P6-14

Background: Denosumab is a fully human monoclonal antibody which inhibits RANKL, a key mediator of osteoclast activity. Results from the primary analysis of this pivotal phase 3 trial showed that denosumab was superior to zoledronic acid (ZA) in dela

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1c0c4e2c71a06b64e6ec2db4d41e1cee
https://doi.org/10.1158/0008-5472.sabcs10-p6-14-01

Zobrazit plný text záznamu

Abstract P1-13-05: The Effect of Treatment with Denosumab or Zoledronic Acid on Health-Related Quality of Life in Patients with Metastatic Breast Cancer

Autor: Yi Qian, Y Zhao, Katia Tonkin, J.J. Body, Qi Jiang, Allan Lipton, Roger Dansey, Ada Braun, Donald L. Patrick, Karen Chung, Lesley Fallowfield

Publikováno v: Cancer Research. 70:P1-13

Background: Patients with breast cancer and bone metastases often experience skeletal-related events (SREs) and pain, which may impact health-related quality of life (HRQoL). Denosumab is a fully human monoclonal antibody against RANKL shown to be su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4a2112b34f400733fe7622251310054
https://doi.org/10.1158/0008-5472.sabcs10-p1-13-05

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání